Focused ultrasound (FUS) is a disruptive medical technology, and its implementation in the
clinic represents the culmination of decades of research. Lying at the convergence of …

Objective To investigate the effects of monoclonal antibodies against Aβ on cognition,
function, amyloid PET and other biomarkers, as well as risk for amyloid-related imaging …

Aducanumab has been approved by the US Food and Drug Administration for treatment of
Alzheimer's disease (AD). Clinicians require guidance on the appropriate use of this new …

Background A hallmark of Alzheimer's disease is the accumulation of amyloid-β (Aβ)
peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being …

On 7 June 2021, aducanumab was granted accelerated approval for the treatment of
Alzheimer disease (AD) by the FDA on the basis of amyloid-lowering effects considered …

Background and Objectives The goal of this work was to investigate the natural history and
outcomes after treatment for spontaneous amyloid-related imaging abnormalities (ARIA)-like …

The ε4 allele of the apolipoprotein E (APOE) gene is the strongest genetic risk factor for late-
onset Alzheimer's disease (AD) and greatly influences the development of amyloid-β (Aβ) …

Cerebral microbleeds (CMBs) are defined as hypointense foci visible on T2*-weighted and
susceptible-weighted MRI sequences. CMBs are increasingly recognised with the …

Cerebral amyloid angiopathy is a common small vessel disease in the elderly involving
vascular amyloid-β deposition. Cerebral amyloid angiopathy is one of the leading causes of …

Numerous clinical trials of anti‐amyloid beta (Aβ) immunotherapy in Alzheimer's disease
have been performed. None of these have provided convincing evidence for beneficial …